Roger R Dmochowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7103798/publications.pdf

Version: 2024-02-01

246 papers

6,082 citations

94269

h-index

88477

70 g-index

278

all docs

278

docs citations

278

times ranked

4032

citing authors

#	Article	IF	CITATIONS
1	Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. Journal of Urology, 2010, 184, 2416-2422.	0.2	352
2	OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. Journal of Urology, 2013, 189, 2186-2193.	0.2	347
3	Detrusor Underactivity and the Underactive Bladder: A New Clinical Entity? A Review of Current Terminology, Definitions, Epidemiology, Aetiology, and Diagnosis. European Urology, 2014, 65, 389-398.	0.9	303
4	Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence. Journal of Urology, 2003, 170, 1259-1263.	0.2	294
5	Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 2003, 62, 237-242.	0.5	271
6	Update of AUA Guideline on the Surgical Management of Female Stress Urinary Incontinence. Journal of Urology, 2010, 183, 1906-1914.	0.2	255
7	A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis. European Urology, 2012, 62, 877-890.	0.9	231
8	Autologous Muscle Derived Cells for Treatment of Stress Urinary Incontinence in Women. Journal of Urology, 2014, 192, 469-476.	0.2	108
9	Impact of overactive bladder on women in the United States:results of a national survey. Current Medical Research and Opinion, 2007, 23, 65-76.	0.9	103
10	Urodynamic Effects of Once Daily Tadalafil in Men With Lower Urinary Tract Symptoms Secondary to Clinical Benign Prostatic Hyperplasia: A Randomized, Placebo Controlled 12-Week Clinical Trial. Journal of Urology, 2010, 183, 1092-1097.	0.2	102
11	Association of Coworker Reports About Unprofessional Behavior by Surgeons With Surgical Complications in Their Patients. JAMA Surgery, 2019, 154, 828.	2.2	98
12	International Continence Society consensus on the diagnosis and treatment of nocturia. Neurourology and Urodynamics, 2019, 38, 478-498.	0.8	94
13	The Burden of Overactive Bladder on US Public Health. Current Bladder Dysfunction Reports, 2016, 11, 8-13.	0.2	93
14	Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World Journal of Urology, 2005, 23, 263-270.	1.2	89
15	Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study. Urology, 2008, 71, 449-454.	0.5	88
16	Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. Urology, 2010, 75, 62-68.	0.5	86
17	Use of Unsolicited Patient Observations to Identify Surgeons With Increased Risk for Postoperative Complications. JAMA Surgery, 2017, 152, 522.	2.2	86
18	Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB). Neurourology and Urodynamics, 2018, 37, 2928-2931.	0.8	81

#	Article	IF	CITATIONS
19	Botulinum toxin A in the overactive bladder: current status and future directions. BJU International, 2007, 99, 247-262.	1.3	73
20	Toileting Behaviors of Womenâ€"What is Healthy?. Journal of Urology, 2019, 201, 129-134.	0.2	72
21	Does central sensitization help explain idiopathic overactive bladder?. Nature Reviews Urology, 2016, 13, 481-491.	1.9	70
22	A review of published anticholinergic scales and measures and their applicability in database analyses. Archives of Gerontology and Geriatrics, 2020, 87, 103885.	1.4	69
23	Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a longâ€ŧerm extension study. Neurourology and Urodynamics, 2017, 36, 368-375.	0.8	64
24	Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU International, 2005, 96, 1049-1054.	1.3	61
25	Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and metaâ€analysis. Neurourology and Urodynamics, 2021, 40, 28-37.	0.8	61
26	Efficacy and Safety of Polyacrylamide Hydrogel for the Treatment of Female Stress Incontinence: A Randomized, Prospective, Multicenter North American Study. Journal of Urology, 2014, 192, 843-849.	0.2	59
27	Foundational Statistical Principles in Medical Research: Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value. Medicina (Lithuania), 2021, 57, 503.	0.8	57
28	Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention?. Neurourology and Urodynamics, 2005, 24, 638-642.	0.8	55
29	Efficacy and Tolerability of Tolterodine Extended Release in Male and Female Patients with Overactive Bladder. European Urology, 2007, 51, 1054-1064.	0.9	55
30	Stress urinary incontinence surgery trends in academic female pelvic medicine and reconstructive surgery urology practice in the setting of the food and drug administration public health notifications. Neurourology and Urodynamics, 2017, 36, 1155-1160.	0.8	53
31	Patient Complaints and Adverse Surgical Outcomes. American Journal of Medical Quality, 2016, 31, 415-422.	0.2	50
32	Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourology and Urodynamics, 2015, 34, 675-678.	0.8	49
33	Postoperative pain outcomes after transvaginal mesh revision. International Urogynecology Journal, 2015, 26, 65-69.	0.7	47
34	Epidemiology of Blunt Lower Urinary Tract Trauma With and Without Pelvic Fracture. Urology, 2017, 102, 234-239.	0.5	47
35	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (IClâ€RS 2015). Neurourology and Urodynamics, 2017, 36, 882-893.	0.8	44
36	Primary Endoscopic Realignment of Urethral Disruption Injuriesâ€"A Double-Edged Sword?. Journal of Urology, 2015, 194, 1022-1026.	0.2	42

3

#	Article	IF	CITATIONS
37	Cystectomy With Urinary Diversion for Benign Disease: Indications and Outcomes. Urology, 2014, 83, 1433-1437.	0.5	41
38	Incontinence rates after midurethral sling revision forÂvaginalÂexposureÂorÂpain. American Journal of Obstetrics and Gynecology, 2016, 215, 764.e1-764.e5.	0.7	37
39	A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. International Urology and Nephrology, 2018, 50, 2153-2165.	0.6	37
40	Mixed incontinence: Current evidence and future perspectives. Neurourology and Urodynamics, 2010, 29, 618-622.	0.8	36
41	The Impact of Pallidal and Subthalamic Deep Brain Stimulation on Urologic Function in Parkinson's Disease. Neuromodulation, 2016, 19, 717-723.	0.4	36
42	Evaluating the Role of Operative Repair of Extraperitoneal Bladder Rupture Following Blunt Pelvic Trauma. Journal of Urology, 2016, 195, 661-665.	0.2	36
43	Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU International, 2009, 104, 294-297.	1.3	34
44	Pelvic Organ Prolapse Surgery in Academic Female Pelvic Medicine and Reconstructive Surgery Urology Practice in the Setting of the Food and Drug Administration Public Health Notifications. Urology, 2016, 91, 46-51.	0.5	34
45	Erectile Dysfunction Following Pelvic Fracture Urethral Injury. Sexual Medicine Reviews, 2018, 6, 114-123.	1.5	34
46	Pelvic organ prolapse (POP) surgery: the evidence for the repairs. BJU International, 2011, 107, 1704-1719.	1.3	32
47	Relationship Between Time in the Operating Room and Incident Pressure Ulcers. American Journal of Medical Quality, 2015, 30, 591-597.	0.2	31
48	The Impact of Urethral Risk Factors on Transcorporeal Artificial Urinary Sphincter Erosion Rates and Device Survival. Journal of Urology, 2015, 194, 1692-1696.	0.2	28
49	Safety and Efficacy of Sling for Persistent Stress Urinary Incontinence After Bulking Injection. Urology, 2011, 77, 1076-1080.	0.5	26
50	Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins, 2016, 8, 88.	1.5	26
51	Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. Neurourology and Urodynamics, 2019, 38, 825-837.	0.8	26
52	Radiofrequency for the treatment of stress urinary incontinence in women. Current Urology Reports, 2009, 10, 369-374.	1.0	25
53	Management of Female and Functional Urology Patients During the COVID Pandemic. European Urology Focus, 2020, 6, 1049-1057.	1.6	25
54	Advancements in minimally invasive treatments for female stress urinary incontinence: Radiofrequency and bulking agents. Current Urology Reports, 2003, 4, 350-355.	1.0	24

#	Article	IF	CITATIONS
55	How can we develop a more clinically useful and robust algorithm for diagnosing and treating nocturia? IClâ€RS 2017. Neurourology and Urodynamics, 2018, 37, S46-S59.	0.8	24
56	Mixed incontinence: definitions, outcomes, and interventions. Current Opinion in Urology, 2005, 15, 374-379.	0.9	23
57	Improving the Tolerability of Anticholinergic Agents in the Treatment of Overactive Bladder. Drug Safety, 2005, 28, 583-600.	1.4	23
58	Toileting Behaviors and Bladder Symptoms in Women Who Limit Restroom Use at Work: A Cross-Sectional Study. Journal of Urology, 2019, 202, 1008-1014.	0.2	23
59	Update on the treatment of overactive bladder. Current Opinion in Urology, 2011, 21, 286-290.	0.9	22
60	Mixed incontinence and cystocele: postoperative urge symptoms are not predicted by preoperative urodynamics. International Urogynecology Journal, 2011, 22, 321-325.	0.7	22
61	Urodynamic Effects of Once Daily Tadalafil in Men With Lower Urinary Tract Symptoms Secondary to Clinical Benign Prostatic Hyperplasia: A Randomized, Placebo Controlled 12-Week Clinical Trial. Journal of Urology, 2013, 189, S135-40.	0.2	22
62	Urinary Diversions After Radiation for Prostate Cancer: Indications and Treatment. Urology, 2014, 84, 702-706.	0.5	22
63	Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. Expert Review of Medical Devices, 2017, 14, 3-14.	1.4	22
64	Advances in drug delivery: Improved bioavailability and drug effect. Current Urology Reports, 2002, 3, 439-444.	1.0	21
65	Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder. Value in Health, 2010, 13, 251-257.	0.1	21
66	Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials. Journal of Urology, 2018, 200, 604-611.	0.2	21
67	Overactive bladder in men: special considerations for evaluation and management. Urology, 2002, 60, 56-62.	0.5	20
68	Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation. International Urogynecology Journal, 2008, 19, 277-282.	0.7	20
69	Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. Neurourology and Urodynamics, 2016, 35, 293-298.	0.8	20
70	Seventh International Consultation on Incontinenceâ€"Research society 2017. Neurourology and Urodynamics, 2018, 37, S6.	0.8	20
71	Methods and results of urethrolysis. Current Urology Reports, 2006, 7, 384-394.	1.0	19
72	Autologous Pubovaginal Sling for the Treatment of Concomitant Female Urethral Diverticula and Stress Urinary Incontinence. Urology, 2015, 85, 1300-1303.	0.5	19

#	Article	IF	Citations
73	The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? IClâ€RS 2017 think thank, Bristol. Neurourology and Urodynamics, 2018, 37, S99-S107.	0.8	19
74	Aging increases the expression of vasopressin receptors in both the kidney and urinary bladder. Neurourology and Urodynamics, 2019, 38, 393-397.	0.8	19
75	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. European Urology, 2019, 75, 129-168.	0.9	19
76	Why Do Women Not Use the Bathroom? Women's Attitudes and Beliefs on Using Public Restrooms. International Journal of Environmental Research and Public Health, 2020, 17, 2053.	1.2	19
77	Pharmacokinetics of Oxybutynin Chloride Topical Gel. Clinical Drug Investigation, 2011, 31, 559-571.	1.1	18
78	Case reports: periurethral bulking agents and presumed urethral diverticula. International Urogynecology Journal, 2011, 22, 1039-1043.	0.7	18
79	Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome. Neurourology and Urodynamics, 2017, 36, 610-613.	0.8	18
80	External electrical stimulation compared with intravaginal electrical stimulation for the treatment of stress urinary incontinence in women: A randomized controlled noninferiority trial. Neurourology and Urodynamics, 2019, 38, 1834-1843.	0.8	18
81	Blinding in Clinical Trials: Seeing the Big Picture. Medicina (Lithuania), 2021, 57, 647.	0.8	18
82	An American Association for the Surgery of Trauma (AAST) prospective multi-center research protocol: outcomes of urethral realignment versus suprapubic cystostomy after pelvic fracture urethral injury. Translational Andrology and Urology, 2018, 7, 512-520.	0.6	18
83	Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?. Current Urology Reports, 2006, 7, 405-413.	1.0	17
84	Vesicovaginal fistula following a transobturator midurethral sling procedure. International Urogynecology Journal, 2007, 18, 113-115.	0.7	17
85	Overactive bladder in males. Therapeutic Advances in Urology, 2009, 1, 209-221.	0.9	17
86	Mirabegron for Male Lower Urinary Tract Symptoms. Current Urology Reports, 2013, 14, 580-584.	1.0	17
87	Difference between Urethral Circumference and Artificial Urinary Sphincter Cuff Size, and its Effect on Postoperative Incontinence. Journal of Urology, 2014, 191, 138-142.	0.2	17
88	Somatic syndromes and chronic pain in women with overactive bladder. Neurourology and Urodynamics, 2017, 36, 1113-1118.	0.8	17
89	<p>Particulate Versus Non-Particulate Bulking Agents In The Treatment Of Stress Urinary Incontinence</p> . Research and Reports in Urology, 2019, Volume 11, 299-310.	0.6	17
90	Women's Perceptions of Public Restrooms and the Relationships with Toileting Behaviors and Bladder Symptoms: A Cross-Sectional Study. Journal of Urology, 2020, 204, 310-315.	0.2	15

#	Article	IF	CITATIONS
91	Transdermal drug delivery treatment for overactive bladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 513-520.	0.7	14
92	Reducing intraoperative red blood cell unit wastage in a large academic medical center. Transfusion, 2015, 55, 2752-2758.	0.8	14
93	Urinary retention and catheter use among U.S. female Medicare beneficiaries: Prevalence and risk factors. Neurourology and Urodynamics, 2017, 36, 2101-2108.	0.8	14
94	Temporal summation to thermal stimuli is elevated in women with overactive bladder syndrome. Neurourology and Urodynamics, 2017, 36, 1108-1112.	0.8	14
95	The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. Urology, 2019, 127, 1-8.	0.5	14
96	Patient Characteristics that May Influence the Effect of Urethral Injection Therapy for Female Stress Urinary Incontinence. Journal of Urology, 2019, 202, 125-131.	0.2	14
97	Nocturia: Evaluation and Current Management Strategies. Reviews in Urology, 2018, 20, 1-6.	0.9	14
98	Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity. BJU International, 2017, 119, 926-932.	1.3	13
99	Desmopressin acetate nasal spray for adults with nocturia. Expert Review of Clinical Pharmacology, 2017, 10, 1281-1293.	1.3	13
100	Evaluating the Role of Postoperative Oral Antibiotic Administration in Artificial Urinary Sphincter and Inflatable Penile Prosthesis Explantation: A Nationwide Analysis. Urology, 2018, 111, 92-98.	0.5	13
101	Impact of food and drinks on urine production: A systematic review. International Journal of Clinical Practice, 2020, 74, e13539.	0.8	13
102	The q-t interval and antimuscarinic drugs. Current Urology Reports, 2005, 6, 405-409.	1.0	12
103	The puzzle of overactive bladder: controversies, inconsistencies, and insights. International Urogynecology Journal, 2006, 17, 650-658.	0.7	12
104	Antimuscarinic therapy in men with lower urinary tract symptoms: What is the evidence?. Current Urology Reports, 2006, 7, 462-467.	1.0	12
105	Measuring urgency in clinical practice. World Journal of Urology, 2009, 27, 739-745.	1.2	12
106	Contemporary Comparison Between Retropubic Midurethral Sling and Autologous Pubovaginal Sling for Stress Urinary Incontinence After the FDA Advisory Notification. Urology, 2015, 85, 321-325.	0.5	12
107	Expert Panel Recommendations on Lower Urinary Tract Health of Women Across Their Life Span. Journal of Women's Health, 2016, 25, 1086-1096.	1.5	12
108	The role of male slings in post prostatectomy incontinence: IClâ€RS 2015. Neurourology and Urodynamics, 2017, 36, 927-934.	0.8	12

#	Article	IF	Citations
109	Phenotyping women with detrusor underactivity by presumed etiology: Is it plausible?. Neurourology and Urodynamics, 2017, 36, 1151-1154.	0.8	12
110	Perioperative complications of conduit urinary diversion with concomitant cystectomy for benign indications: A populationâ€based analysis. Neurourology and Urodynamics, 2017, 36, 1411-1416.	0.8	12
111	Detrusor underactivity in women: A current understanding. Neurourology and Urodynamics, 2019, 38, 2070-2076.	0.8	12
112	An enhanced recovery program in colorectal surgery is associated with decreased organ level rates of complications: a difference-in-differences analysis. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 2222-2230.	1.3	12
113	Penile Prosthesis Insertion in the Era of Antibiotic Stewardship—Are Postoperative Antibiotics Necessary?. Journal of Urology, 2020, 203, 611-614.	0.2	12
114	Treatment of mixed urinary incontinence. Central European Journal of Urology, 2011, 64, 120-126.	0.2	12
115	Urodynamic Effects of Once-Daily Tadalafil in Men with LUTS Secondary to Clinical BPH. Current Urology Reports, 2010, 11, 254-260.	1.0	11
116	An Evidence-Based Protocol for Antibiotic Use Prior to Cystoscopy Decreases Antibiotic Use without Impacting Post-Procedural Symptomatic Urinary Tract Infection Rates. Journal of Urology, 2018, 199, 1004-1010.	0.2	11
117	Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation. Journal of Urology, 2018, 200, 856-861.	0.2	11
118	Overactive bladder pharmacotherapy: what does the future hold?. BJU International, 2007, 99, 13-16.	1.3	10
119	Treatment of Pelvic Floor Disorders Following Neobladder. Current Urology Reports, 2017, 18, 5.	1.0	10
120	Road to recovery after transvaginal surgery for urethral mesh perforation: evaluation of outcomes and subsequent procedures. International Urogynecology Journal, 2018, 29, 887-892.	0.7	10
121	A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US. Patient Preference and Adherence, 2018, Volume 12, 2139-2152.	0.8	10
122	Initial clinical experience with selective bladder denervation for refractory overactive bladder. Neurourology and Urodynamics, 2019, 38, 644-652.	0.8	10
123	Nocturia and electrocardiographic abnormalities among patients at an innerâ€city cardiology clinic. Neurourology and Urodynamics, 2021, 40, 509-514.	0.8	10
124	Office Urodynamics. Urologic Clinics of North America, 2005, 32, 353-370.	0.8	9
125	The clinical efficacy of tolterodine extended-release is maintained for $24\hat{a} \in f$ h in patients with overactive bladder. BJU International, 2007, 100, 107-110.	1.3	9
126	Benchmarking the Use of a Rapid Response Team by Surgical Services at a Tertiary Care Hospital. Journal of the American College of Surgeons, 2014, 218, 66-72.	0.2	9

#	Article	IF	CITATIONS
127	Temporal Trends in Conduit Urinary Diversion With Concomitant Cystectomy for Benign Indications: A Population-based Analysis. Urology, 2016, 98, 70-74.	0.5	9
128	Cost-effective management of pelvic fracture urethral injuries. World Journal of Urology, 2017, 35, 1617-1623.	1.2	9
129	Postoperative Complications of Patients With Spina Bifida Undergoing Urologic Laparotomy: A Multi-institutional Analysis. Urology, 2017, 108, 233-236.	0.5	9
130	Painful Bladder Symptoms Related to Somatic Syndromes in a Convenience Sample of Community Women with Overactive Bladder Symptoms. Journal of Urology, 2018, 200, 1332-1337.	0.2	9
131	Surgery for female SUI: The ICI algorithm. Neurourology and Urodynamics, 2019, 38, S21-S27.	0.8	8
132	How can we improve the diagnosis and management of bladder pain syndrome? Part 2:IClâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S71-S81.	0.8	8
133	Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. Expert Opinion on Pharmacotherapy, 2002, 3, 443-454.	0.9	7
134	Direct visual internal urethrotomy for isolated, post-urethroplasty strictures: a retrospective analysis. Therapeutic Advances in Urology, 2017, 9, 39-44.	0.9	7
135	New technology assessment and current and upcoming therapies for underactive bladder. Neurourology and Urodynamics, 2018, 37, 2932-2937.	0.8	7
136	Women With Overactive Bladder Exhibit More Unhealthy Toileting Behaviors: A Cross-sectional Study. Urology, 2019, 134, 97-102.	0.5	7
137	Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 103-110.	1.5	7
138	Factors associated with urinary incontinence in a community sample of young nulligravid women. Neurourology and Urodynamics, 2020, 39, 1430-1436.	0.8	7
139	Urinary Incontinence: Proper Assessment and Available Treatment Options. Journal of Women's Health, 2005, 14, 906-916.	1.5	6
140	Transâ€Vaginal Mesh Revision: A Comprehensive Review on Etiologies and Management Strategies with Emphasis on Postoperative Pain Outcomes. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 69-75.	0.6	6
141	Trends in urodynamics in U.S. female medicare beneficiaries, 2000–2010. Neurourology and Urodynamics, 2015, 34, 420-423.	0.8	6
142	Clinical Utility of Routine Follow-up Cystography in the Management of Traumatic Bladder Ruptures. Urology, 2018, 113, 230-234.	0.5	6
143	Economic Burden of Illness in Adult Patients with Nocturia. Journal of Managed Care & Decialty Pharmacy, 2019, 25, 593-604.	0.5	6
144	The International Continence Society (ICS) report on the terminology for male lower urinary tract surgery. Neurourology and Urodynamics, 2020, 39, 2072-2088.	0.8	6

#	Article	IF	CITATIONS
145	Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis. Urology, 2020, 140, 7-13.	0.5	6
146	Foundational Statistical Principles in Medical Research: A Tutorial on Odds Ratios, Relative Risk, Absolute Risk, and Number Needed to Treat. International Journal of Environmental Research and Public Health, 2021, 18, 5669.	1.2	6
147	Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder. Journal of Urology, 2019, 201, 573-580.	0.2	6
148	Association of Knowledge and Presence of Pelvic Floor Disorders and Participation in Pelvic Floor Exercises: A Cross-sectional Study. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 310-314.	0.6	6
149	Recent Antibiotic Treatment Increases the Risk of Urinary Tract Infection after Outpatient Cystoscopy. Urology Practice, 2016, 3, 90-96.	0.2	5
150	Under what circumstances should stress incontinence surgery be performed at the same time as prolapse surgery? IClâ€RS 2015. Neurourology and Urodynamics, 2017, 36, 909-914.	0.8	5
151	Management of Voiding Dysfunction After Female Neobladder Creation. Current Urology Reports, 2017, 18, 33.	1.0	5
152	Oneâ€year results with selective bladder denervation in women with refractory overactive bladder. Neurourology and Urodynamics, 2019, 38, 2178-2184.	0.8	5
153	The Epidemiology and Population-Based Studies of Women with Lower Urinary Tract Symptoms: A Systematic Review., 2022, 48, 155-165.		5
154	Bladder neck pubovaginal slings. Expert Review of Medical Devices, 2005, 2, 327-340.	1.4	4
155	Oxybutynin gel for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy, 2012, 13, 1337-1343.	0.9	4
156	Biologic Materials for Pelvic Floor Reconstruction. Current Bladder Dysfunction Reports, 2012, 7, 201-209.	0.2	4
157	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: IClâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S66-S70.	0.8	4
158	An Evaluation of Longitudinal Measures of Anticholinergic Exposure for Application in Retrospective Administrative Data Analyses. Advances in Therapy, 2019, 36, 2247-2259.	1.3	4
159	A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder. Neurourology and Urodynamics, 2019, 38, 660-667.	0.8	4
160	The inFlow intraurethral valve-pump for women with detrusor underactivity: A summary of peer-reviewed literature. Journal of Spinal Cord Medicine, 2022, 45, 489-497.	0.7	4
161	A randomized, placeboâ€controlled clinical development program exploring the use of litoxetine for treating urinary incontinence. Neurourology and Urodynamics, 2021, 40, 1515-1523.	0.8	4
162	Compensatory bladder behaviors ("copingâ€) in women with overactive bladder. Neurourology and Urodynamics, 2022, 41, 195-202.	0.8	4

#	Article	IF	CITATIONS
163	The burdens of incontinence: Quantifying incontinence product usage and costs in women. Neurourology and Urodynamics, 2022, 41, 1601-1611.	0.8	4
164	GAG Layer Replenishment Therapy for Recurrent Infectious Bladder Dysfunction. Current Bladder Dysfunction Reports, 2012, 7, 113-119.	0.2	3
165	Symptomatic Urinary Tract Infections in Renal Transplant Recipients afterÂCystoscopy for Ureteral Stent Removal. Urology Practice, 2017, 4, 405-411.	0.2	3
166	Urinary-cutaneous Fistulae Following Conservative Management of Extraperitoneal Bladder Ruptures. Urology, 2017, 109, 195-200.	0.5	3
167	Minimal Inpatient Narcotic Requirement and Immediate Complication Profile Supports Same Day Discharge Following Artificial Urinary Sphincter Insertion. Urology Practice, 2020, 7, 305-308.	0.2	3
168	Stress Urinary Incontinence in Women with Neurogenic Voiding Dysfunction. Current Bladder Dysfunction Reports, 2010, 5, 142-149.	0.2	2
169	Safety and efficacy of a patientâ€controlled bladder management system for treating urinary retention in men. Neurourology and Urodynamics, 2016, 35, 630-635.	0.8	2
170	Cystectomy for Neurogenic Bladder. Current Bladder Dysfunction Reports, 2016, 11, 341-345.	0.2	2
171	Diagnosis and Management of Male Genital Lichen Sclerosus. Current Bladder Dysfunction Reports, 2016, 11, 234-241.	0.2	2
172	Lessons Learned from Mesh Litigation for Prolapse and Incontinence. Current Bladder Dysfunction Reports, 2016, 11, 73-78.	0.2	2
173	Evaluation and Management of Mid-Urethral Sling Complications. Current Bladder Dysfunction Reports, 2016, 11, 160-168.	0.2	2
174	Delivery methods for drugs used in the treatment of overactive bladder. Expert Opinion on Drug Delivery, 2016, 13, 361-371.	2.4	2
175	Impact of Autonomic Dysfunction on Lower Urinary Tract Symptoms. Current Bladder Dysfunction Reports, 2017, 12, 273-279.	0.2	2
176	Study design and outcomes measures: The influence of composite endpoints and other design variables on outcomes in a study of a novel device for stress urinary incontinence. Neurourology and Urodynamics, 2018, 37, 2919-2927.	0.8	2
177	Nonclinical Barriers to Care for Neurogenic Patients Undergoing Complex Urologic Reconstruction. Urology, 2019, 124, 271-275.	0.5	2
178	Psychological comorbidities and functional neurological disorders in women with idiopathic urinary retention: International Consultation on Incontinence Research Society (IClâ€RS) 2019. Neurourology and Urodynamics, 2020, 39, S60-S69.	0.8	2
179	Should we routinely assess psychological morbidities in idiopathic lower urinary tract dysfunction: IClâ€RS 2019?. Neurourology and Urodynamics, 2020, 39, S70-S79.	0.8	2
180	(S)-oxybutynin (Sepracor). Current Opinion in Investigational Drugs, 2002, 3, 1508-11.	2.3	2

#	Article	IF	CITATIONS
181	Understanding sexual health concerns in women after traumatic pelvic fracture. Neurourology and Urodynamics, 2022, 41, 1364-1372.	0.8	2
182	Mid-urethral slings: surgical evolution as manifest by technology. Nature Reviews Urology, 2007, 4, 242-243.	1.4	1
183	Augmented repairs and use of interposition grafts in pelvic reconstructive surgery: Part II. Current Bladder Dysfunction Reports, 2007, 2, 143-154.	0.2	1
184	Current Concepts in Female Neurogenic Voiding Dysfunction. Current Bladder Dysfunction Reports, 2011, 6, 150-158.	0.2	1
185	Consideration in Quality and Safety for Pelvic Floor Interventions. Current Bladder Dysfunction Reports, 2014, 9, 26-31.	0.2	1
186	The Case for Robotics in Pelvic Prolapse Surgery. Current Bladder Dysfunction Reports, 2014, 9, 1-5.	0.2	1
187	Advances in the Treatment of Urinary Incontinence in Women. Clinical Medicine Insights Urology, 2015, 8, CMU.S13181.	0.4	1
188	What Matters About Overactive Bladder Outcomes. Journal of Women's Health, 2016, 25, 767-767.	1.5	1
189	Early Sacral Neuromodulation in Spinal Cord Injuryâ€"Can It Regenerate Nerves?. Current Bladder Dysfunction Reports, 2016, 11, 350-355.	0.2	1
190	Can men with lower urinary tract symptoms (LUTs) predict voided volumes?. World Journal of Urology, 2020, 38, 1261-1266.	1.2	1
191	Realâ€time daily assessment of work interference on healthcare professionals' restroom use: A pilot study. Neurourology and Urodynamics, 2021, 40, 728-734.	0.8	1
192	First voided volume: A novel approach to characterize nocturia. Neurourology and Urodynamics, 2021, 40, 848-854.	0.8	1
193	Risk Factor of De Novo Urgency and Urge Incontinence After Autologous Fascia Pubovaginal Sling. Research and Reports in Urology, 2021, Volume 13, 591-596.	0.6	1
194	Does urinary urgency drive urinary frequency in overactive bladder?. LUTS: Lower Urinary Tract Symptoms, 2022, , .	0.6	1
195	Urinary frequency: Event measure, outcome significance?. Current Urology Reports, 2005, 6, 87-88.	1.0	0
196	The Q-T interval and antimuscarinic drugs. Current Bladder Dysfunction Reports, 2006, 1, 3-7.	0.2	0
197	Augmented repairs and use of interposition grafts in pelvic reconstructive surgery: Part I. Current Bladder Dysfunction Reports, 2007, 2, 86-94.	0.2	0
198	Muscarinic receptors: What we know. Current Bladder Dysfunction Reports, 2007, 2, 29-36.	0.2	0

#	Article	IF	CITATIONS
199	Are autologous myoblasts and fibroblasts safe and effective for the treatment of stress urinary incontinence in women?. Nature Reviews Urology, 2008, 5, 298-299.	1.4	0
200	Editorial Comment on: Symptom Bother and Health Care–Seeking Behavior among Individuals with Overactive Bladder. European Urology, 2008, 53, 1037-1038.	0.9	0
201	Painful bladder syndrome: Is consensus possible?. Current Bladder Dysfunction Reports, 2009, 4, 86-90.	0.2	0
202	An analysis of potential predictors of outcomes of therapy for urge urinary incontinence. Current Bladder Dysfunction Reports, 2009, 4, 181-181.	0.2	0
203	Painful bladder syndrome: Is consensus possible?. Current Prostate Reports, 2009, 7, 177-181.	0.1	0
204	Current Status of Urodynamics for Evaluation of Incontinence. Current Bladder Dysfunction Reports, 2010, 5, 168-174.	0.2	0
205	Outcomes and Pelvic Floor Interventions: Can We Predict?. Current Bladder Dysfunction Reports, 2010, 5, 119-125.	0.2	0
206	Preface. Urologic Clinics of North America, 2011, 38, xi.	0.8	0
207	Cystocele Repair with Interpositional Grafting. Urologic Clinics of North America, 2011, 38, 47-53.	0.8	0
208	Editorial Comment from Dr Dmochowski to Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, doubleâ€blind, placeboâ€controlled trial. International Journal of Urology, 2011, 18, 374-374.	0.5	0
209	Update on Neuromodulation. Current Bladder Dysfunction Reports, 2011, 6, 135-141.	0.2	0
210	Insertion of an Anterior Transobturator Mesh Kit in the Management of Recurrent Anterior Vaginal Wall Prolapse. Current Bladder Dysfunction Reports, 2011, 6, 111-113.	0.2	0
211	Patient Safety and Surgical Intervention for Urinary Incontinence and Pelvic Organ Prolapse. Current Bladder Dysfunction Reports, 2012, 7, 187-193.	0.2	0
212	Trends in Care Delivery for Disorders of the Female Pelvic Floor. Current Bladder Dysfunction Reports, 2012, 7, 194-200.	0.2	0
213	Mesh for Stress Incontinence. Current Bladder Dysfunction Reports, 2012, 7, 210-214.	0.2	0
214	Prostate Related Urinary Tract Infections. Current Bladder Dysfunction Reports, 2013, 8, 197-202.	0.2	0
215	Botox for the Neurogenic Bladder. Current Bladder Dysfunction Reports, 2013, 8, 312-318.	0.2	0
216	Elucidation of Phosphodiesterase Type 5 Inhibitor Mechanism of Action. Journal of Urology, 2013, 190, 1161-1162.	0.2	0

#	Article	IF	CITATIONS
217	Editorial Comment for Alloussi <i>et al.</i> . Journal of Endourology, 2014, 28, 89-89.	1.1	O
218	Emerging treatments for urinary incontinence. Expert Opinion on Emerging Drugs, 2014, 19, 281-290.	1.0	0
219	Editorial Comment. Urology, 2014, 83, 548-549.	0.5	O
220	Post-Prostatectomy Incontinenceâ€"A Clinical GuideSinglaA.K.: Post-Prostatectomy Incontinenceâ€"A Clinical Guide. Saarbrücken, Germany: Lambert Academic Publishing2013. 212 pages Journal of Urology, 2014, 192, 620-620.	0.2	0
221	Editorial Comment. Journal of Urology, 2015, 193, 1310-1310.	0.2	O
222	Symptoms alone may lead to inaccurate diagnosis in men with possible bladder outlet obstruction. Evidence-Based Medicine, 2015, 20, 120-120.	0.6	0
223	On Epidemiology: Extrapolations, Foibles, and Fictions. European Urology, 2015, 68, 113-114.	0.9	0
224	Re: Outcome of Transvaginal Mesh and Tape Removed for Pain Only. European Urology, 2015, 67, 1190-1191.	0.9	0
225	Editorial Comment. Journal of Urology, 2016, 196, 1477-1477.	0.2	0
226	Female Urology – Quo Vadis?. Current Opinion in Urology, 2016, 26, 289.	0.9	0
227	Editorial Comment. Urology, 2016, 97, 110.	0.5	0
228	The Non-surgical Options for SUl—Is Any One Optimal?. Current Bladder Dysfunction Reports, 2016, 11, 66-72.	0.2	0
229	Academic Urological Surgeons have Greater Exposure to Risk Management Activity than Community Urological Surgeons: An Empirical Analysis of Patient Complaint Data. Urology Practice, 2017, 4, 437-443.	0.2	0
230	Editorial Comment. Journal of Urology, 2017, 197, 749-750.	0.2	0
231	Editorial Comment. Journal of Urology, 2017, 198, 159-159.	0.2	0
232	Author Reply. Urology, 2018, 111, 98.	0.5	0
233	Effects of Pelvic Organ Prolapse on the Bladder. Current Bladder Dysfunction Reports, 2018, 13, 118-124.	0.2	0
234	Proximal location of explanted midurethral slings is associated with urinary storage symptoms. Neurourology and Urodynamics, 2019, 38, 1611-1615.	0.8	0

#	Article	IF	CITATIONS
235	Author Reply. Urology, 2019, 124, 275.	0.5	O
236	Editorial Comment. Urology, 2019, 132, 206.	0.5	0
237	Back Cover Image, Volume 38, Number 7, September 2019. Neurourology and Urodynamics, 2019, 38, ii.	0.8	O
238	AUTHOR REPLY. Urology, 2020, 144, 276.	0.5	0
239	Ninth International Consultation on Incontinence—Research Society 2019: Introduction. Neurourology and Urodynamics, 2020, 39, S7-S8.	0.8	O
240	Associations between nighttime and daytime maximum voided volumes: Relevance for nocturia?. Neurourology and Urodynamics, 2020, 39, 2301-2304.	0.8	0
241	Editorial Comment. Journal of Urology, 2021, 205, 1753-1754.	0.2	O
242	Salvage procedures in reconstructive urology. Central European Journal of Urology, 2013, 66, 487.	0.2	0
243	Urinary incontinence in women: non pharmacologic approaches and newer pharmacotherapies. An update. Minerva Medica, 2017, 108, 255-267.	0.3	O
244	Re: Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder. Journal of Urology, 2019, , 101097JU00000000000274.	0.2	0
245	Letter to the Editor: RE: Neuromuscular treatment approach for women with chronic pelvic pain syndrome improving pelvic pain and functionality by S. Patil et al. <i>Neurourology and Urodynamics</i> in 2022;41:220â€228. Neurourology and Urodynamics, 2022, 41, 1045-1045.	0.8	O
246	Response letter to comments on "Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and metaâ€analysis― Neurourology and Urodynamics, 2022, 41, 518-519.	0.8	0